AEON Biopharma, Inc. (AEON) Stock Price

AEONStock
$0.2174.36%52W
Market Cap$10.57M
P/E0.54x
PEG Ratio
Div yield
Beta0.62

AEON Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-93.62%
Price vs S&P 500 (4W)-25.24%
VGM Score7.23
P/E Ratio (Annual)0.54x

AEON Earnings Surprise History

Q2 25-0.60est. -0.35
Q3 25-0.39est. -0.43
Q4 25-3.72est. -0.20
Q1 26-0.25est. -0.44
Q2 26-0.02est. -0.33

AEON Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
4.13
4.13
4.13
4.11

Industry Peers — Pharmaceuticals(571)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
AEONAEON Biopharma, Inc.
F$0.21
LLYEli Lilly & Co.DBB$1233.66
JNJJohnson & JohnsonDCB$273.14
ABBVABBVIE INC.DCB$265.79
MRKMerck & Co., Inc.DCA$156.45
NVSNovartis AGCCC$159.98
AZNAstraZeneca PLCCBC$169.66
NVONovo-Nordisk A/SBCC$48.66
ABTAbbott LaboratoriesCCB$116.13
PFEPfizer Inc.CDC$28.57
VRTXVertex Pharmaceuticals IncDCB$552.85

About AEON Biopharma, Inc.

AEON Biopharma is a clinical-stage biopharmaceutical company developing ABP-450 (prabotulinumtoxinA), a proprietary botulinum toxin complex for treating debilitating medical conditions. The company is initially focusing on neuroscience indications where there is significant unmet medical need. ABP-450 represents AEON's lead therapeutic program aimed at patients with conditions that have limited treatment options.